Regen Biopharma issues 55.8M Series A Preferred shares to settle $376,711 in convertible debt

Regen BioPharma Inc

Issued 55,809,233 Series A Preferred shares to satisfy $250,000 principal and $126,711 accrued interest on convertible promissory notes.
Shares issued directly by management under Section 4(a)(2) exemption; no underwriters or commissions paid.
As of Nov 21, 2022, $510,000 of convertible notes outstanding, including $360,000 convertible at floating rate.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.